Overview

Incidence of Non Adherence to Treatment With Once-daily Formulation of Tacrolimus

Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Aim The primary objective of this study is to compare medication adherence with medical therapy in patients receiving once-daily versus twice-daily tacrolimus regimens. Participants 60 adult renal transplant patients randomized 1:2 into twice-daily and once-daily tacrolimus groups Outcomes The primary outcome will be medication adherence to the once-daily and twice-daily regimens, measured in terms of implementation. Secondary outcomes will include graft and patient survival, renal function and adverse events. Follow up - 12 months
Phase:
Phase 3
Details
Lead Sponsor:
Rabin Medical Center
Collaborators:
Astellas Pharma Inc
Teva Pharma
Treatments:
Tacrolimus